Live Breaking News & Updates on Company Named Patient Program

Stay updated with breaking news from Company named patient program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Antengene Announces XPOVIO® Regulatory Approval in Hong Kong for the Treatment of Relapsed and/or Refractory Multiple Myeloma

/PRNewswire/ Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to. ....

United States , United Kingdom , Northern Ireland , Hong Kong , South Korea , Thomas Karalis , Asia Pacific , Peter Qian , Hong Kongchina , Jay Mei , Prnewswire Antengene Corporation Limited , Department Of Health , Karyopharm Therapeutics Inc , Antengene Corporation Limited , Company Named Patient Program , European Society Of Medical Oncology , Hong Kong Stock Exchange , European Union , International Myeloma Foundation , Company Annual , International Myeloma Working Group , National Cancer Care Network , Chinese Society Of Clinical Oncology , Antengene Corporation , Cancer Association Guidelines For The Holistic , Taiwan China ,